Schizophrenia

Vitamin D deficiency (VDD) is an important factor in the pathogens of schizophrenia.

Current evidence and data regarding clozapine-resistant schizophrenia is unclear, but new treatment options are on the horizon that could show promise.

Health care professionals providing care to patients using second-generation antipsychotics could benefit from incorporating community pharmacists as members of their team.

These therapies can improve treatment adherence for patients, especially for those with a history of poor or uncertain adherence.

Pharmacists can educate patients on current clinical evidence of cannabis’s therapeutic benefit, as well as cannabis’s complexities, risks, and potential adverse effects.

Investigators suggested that this difference is caused by a common medication for treatment-resistant schizophrenia.

This disease can, at the very least, help researchers to “identify” the floodgates to definitive tests and therapies for complex psychological and neurological diseases, expert says.

Pharmacists working with patients with mental health conditions are able to optimize medication use and improve adherence.

Evidence shows vitamin D deficiency is linked to abnormal dopamine signaling disorders in neurodevelopment, including schizophrenia.

Pharmacogenomics is gaining support in mental health and polypharmacy, where the data make a strong case for improvements in clinical and economic outcomes.

The ease of administration with new agents for schizophrenia via an injection is advantageous because this patient population is commonly agitated and difficult to administer oral medications to.

The study will assess the use of the drug to treat impaired social motivation, or asociality, which is a difficult-to-treat symptom of schizophrenia that can cause significant functional impairment.

The estimated cost burden of schizophrenia is more than $150 billion, consisting of direct treatment cost and lost productivity.

Mental health interventions are a critical part of the global response to HIV, with multiple potential roles for psychiatrists and other mental health professionals.

The flexible 1- and 2-month dosing intervals of risperidone could help address adherence challenges common with schizophrenia treatments.

The formulation in 960 mg and 720 mg prefilled syringes delivers sustained plasma concentrations comparable to those demonstrated in studies with Abilify Maintena.

Therapy from Karuna Therapeutics demonstrates an 8.4-point reduction in Positive and Negative Syndrome Scale total score compared with the placebo at week 5.

The study clarifies why serotonin-based therapeutics, such as selective serotonin reuptake inhibitors, do not promote neuroplasticity in the same ways as psychedelics and other psychoplastogenic therapeutics.

Austedo XR will be available in 3 extended-release tablet strengths, which provides an updated regimen that may result in a lower pill count for patients.

The CBD gummy market is being fueled by the desire for alternative, natural treatment options.

The findings suggest that reduced gray matter is not the cause of psychiatric illness, although it is found in regions of the brain associated with it.

The atypical antipsychotic is an extended-release injectable suspension that is administered bi-weekly.

Cariprazine (Vraylar; AbbVie, Gedeon Richter) is indicated as an adjunctive therapy to antidepressants for treating adult patients with major depressive disorder.

New research about the risks of dementia in patients with non-affective psychotic disorders could help shape new life course models for prevention.

Pharmacists dispensing Lybalvi should understand that potentially life-threatening consequences can occur if opioids are taken concurrently.

Following the success of the phase 3 EMERGENT-2 trial, researchers suggest that xanomeline-trospium could be a safe and effective treatment option for adults with schizophrenia.

The New Drug Application for aripiprazole 2-month, ready-to-use, long-acting injectable could lead to the first FDA approval of a 2-month schizophrenia and bipolar I disorder antipsychotic treatment.

The mainstay of treatment for schizophrenia and schizoaffective disorder includes antipsychotics.

Study results show that the risk of gaining 10% or more of body weight from the baseline fell 50% when patients were on the combination.

Investigators also report that the therapy could mimic the efficacy of olanzapine but cancelled out the medication-induced weight gain, improving symptoms and outcomes.